Article

Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinoma

2025-11-26

Abstract excerpt

Lung adenocarcinoma (LUAD) is a leading cause of cancer death worldwide, with RAS signalling as a key oncogenic driver. Although KRAS mutations have been linked to immune evasion in preclinical models, the relationship between RAS activity and tumour immunity or response to immunotherapy in patients remains unclear. Here, we applied our previously validated RAS84 transcriptional signature to stratify LUAD patient...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0f125a25-dcd4-53d7-a170-c6233343da17
DOI: 10.1101/2025.11.25.690426

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinomaDOI 10.1101/2025.11.25.690426Read

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for ImmunotherapySemantic proximity Read

Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinomaSemantic proximity Read

The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.Semantic proximity Read

RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.Semantic proximity Read

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.Semantic proximity Read

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinomaSemantic proximity Read

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.Semantic proximity Read

Immune modulatory effects of oncogenic KRAS in cancerSemantic proximity Read

Therapeutic KRAS <sup>G12C</sup> inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancersSemantic proximity Read

Selective inhibition of canonical STAT3 signaling suppresses K-ras mutant lung tumorigenesis and reinvigorates anti-tumor immunity.Semantic proximity Read

Rasal1 impairment unleashes anticancer immunity - a focus on T cellsSemantic proximity Read

Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven CancerSemantic proximity Read